433 related articles for article (PubMed ID: 15140755)
1. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
D'Alessio DA; Vahl TP
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
[TBL] [Abstract][Full Text] [Related]
2. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide 1(GLP-1) in biology and pathology.
Meier JJ; Nauck MA
Diabetes Metab Res Rev; 2005; 21(2):91-117. PubMed ID: 15759282
[TBL] [Abstract][Full Text] [Related]
4. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Nauck MA
Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
[TBL] [Abstract][Full Text] [Related]
6. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.
List JF; Habener JF
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E875-81. PubMed ID: 15140754
[TBL] [Abstract][Full Text] [Related]
9. The physiological role of GLP-1 in human: incretin, ileal brake or more?
Schirra J; Göke B
Regul Pept; 2005 Jun; 128(2):109-15. PubMed ID: 15780430
[TBL] [Abstract][Full Text] [Related]
10. Extrapancreatic effects of GIP and GLP-1.
Vella A; Rizza RA
Horm Metab Res; 2004; 36(11-12):830-6. PubMed ID: 15655715
[TBL] [Abstract][Full Text] [Related]
11. The potential role of glucagon-like peptide 1 in diabetes.
Meier JJ; Nauck MA
Curr Opin Investig Drugs; 2004 Apr; 5(4):402-10. PubMed ID: 15134281
[TBL] [Abstract][Full Text] [Related]
12. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2.
Baggio LL; Drucker DJ
Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):531-54. PubMed ID: 15533774
[TBL] [Abstract][Full Text] [Related]
13. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
Otto Buczkowska E; Dworzecki T
Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
[TBL] [Abstract][Full Text] [Related]
14. [Glucagon-like peptide-1--a new hormone and a new drug].
Holst JJ
Ugeskr Laeger; 1998 Apr; 160(16):2371-7. PubMed ID: 9571809
[TBL] [Abstract][Full Text] [Related]
15. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
Drucker DJ
Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
[TBL] [Abstract][Full Text] [Related]
16. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.
Larsen PJ; Holst JJ
Regul Pept; 2005 Jun; 128(2):97-107. PubMed ID: 15780429
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum.
Hansen L; Hartmann B; Mineo H; Holst JJ
Regul Pept; 2004 Apr; 118(1-2):11-8. PubMed ID: 14759551
[TBL] [Abstract][Full Text] [Related]
20. [Glucagon-like peptide-1(GLP-1)].
Wasada T
Nihon Rinsho; 2004 Jun; 62(6):1175-80. PubMed ID: 15206160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
